Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Conclusion: IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.

Source: Journal of Allergy and Clinical Immunology - March 31, 2014 Category: Allergy & Immunology Authors: Howard Sofen, Stacy Smith, Robert T. Matheson, Craig L. Leonardi, Cesar Calderon, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J. Marciniak, Yasmine Wasfi, Yuhua Wang, Philippe Szapary, James G. Krueger Tags: Atopic dermatitis and skin disease Source Type: research